RESEARCH TRIANGLE PARK, N.C., March 28, 2013 /PRNewswire/ -- Marken today announced a life sciences panel event which will take place on April 11th to explore the key issues and challenges the industry faces with biologics and biosimilar trials in Latin America. Biosimilars have become increasingly attractive to the pharma industry and many Latin American governments are developing abbreviated regulatory pathways for biosimilars. Invited panelists include experts who will share their knowledge, experience, and real examples of some of the economic, political, and regulatory factors that play a role while conducting clinical trials.
Federico Lerner, Senior Director of Operations, Latin America, PRA International
Sashka Dunkerley, Chief Scientific Officer, Novartis
Francisco Garcia, Regional Clinical Monitoring Manager, Sanofi Pasteur
Arturo Rodriguez Jacob, President, Mexican Association of CRO's Mexico at ACROM
Dan Bell, Vice President, Regulatory Compliance and Technical Affairs, Marken
Marken hosts panel events as well as workshops and roundtables all around the globe in order to facilitate information-sharing among experts in the clinical trial arena.
The event coincides with Marken's grand opening for their second GMP-compliant depot located in Mexico City. The new 15,000 square foot facility, which replaces the first depot opened by Marken in 2011, provides secure temperature controlled storage and distribution for pharmaceuticals, biologics, medical devices and diagnostic equipment. The new depot will supplement Marken's existing network of global depots in Germany, Singapore, the US, Argentina, and China.
Space for the panel event is limited. Interested in attending? Please respond to: RSVP.firstname.lastname@example.org
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies.